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THE inability of transplantable tumours to stimulate an effective immune
response, and hence their capacity to proliferate apparently unchecked in the host
animal, may come aboutin severalways. General depressionofimmunereactivity
may be associated with presence of the tumour (reviewed by Grace, 1964), or
there may be a,specific overloading or paralysis ofthe immune reaction by tumour
antigens, accenrtuated by rapid tumour growth, so that surgical removal results in
immunity to subsequent challenge (Pilch and Riggins, 1966; Foley, 1953; Prehn
and Main, 1957). Even ifantibodies are formed, their presence may in some cases
enhance tumour growth (Kaliss, 1965).
Allogeneic tumours, which are transplantable between several or all strains ofa
host species-such as the Ehrlich ascites tumour (E.A.T.) ofmice- are not subject
to homograft rejection and thus it may be argued that their original histocom-
patibility antigens have been lost, inactivated or masked in some way. That
E.A.T. is not devoid ofcharacteristic antigens which are immunogenic in the mouse
is demonstrated by several reports of resistance to subsequent tumour challenge
in animals which have been injected with non-viable tumour cells. Thus heavily
irradiated tumour cells are unable to multiply, but can stimulate a moderately
effective immunity (Revesz, 1960) which is not usually demonstrable with dis-
rupted tumour cell preparations. A highly effective way of rendering E.A.T.
cells immunogenic in vivo is to bring about viral oncolysis in a host animal resis-
tant to the virus employed (Lindenmann, 1964). Chemical treatment of E.A.T.
cells with iodoacetate in vitro has also been used to inhibit their growth whilst
accentuating their antigenic properties, and an intense immunity has been reported
to occur in mice injected with such cells (Apffel, Arnason and Peters, 1966).
We have attempted to confirm the general applicability of the iodoacetate
method of inducing immunity to E.A.T., with the hope that the nature of this
immunity could be further investigated.
MATERIALS AND METHODS
Mice
Initial stocks ofinbred CBA mice were obtained from the Australian National
University, Canberra; Herston white mice were randomly bred in a closed colony
at the University of Queensland. The mice consisted of approximately equal
numbers of males and females, 2-3 months old.
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Tumour
Ehrlich Lettre hyperdiploid ascites tumour was obtained from Dr. E. L.
French (Melbourne) in 1965. It was carried by serial passage in adult CBA mice
up to the 20th passage for the present work.
Immunizing Procedure
Ascites from CBA mice injected 7 to 10 days previously was collected in
heparin and incubated with an equal volume of 0-01 M sodium iodoacetate for
1 hour at 370 C. and pH 7-4. After incubation, the mixture was diluted with
physiological saline and each mouse was injected intraperitoneally with 2-5 x 106
cells in 0-5 ml. of suspending medium. The mice were boosted twice at 14-day
intervals with 2-5 x 106 freshly prepared, iodoacetate-treated cells.
Three batches of mice were immunized as above for subsequent challenge.
Batch I consisted of 15 CBA mice, Batch II, 40 CBA mice and Batch III, 40
Herston white mice. Additional batches of CBA mice were immunized with
various E.A.T. cell preparations (sonicated and iodoacetate-treated cells-see
below) for hypersensitivity testing.
Challenge
After the second booster dose all 3 batches ofmice were divided into 3 groups.
Each group was challenged intraperitoneally with 2-5 x 106 live, fresh E.A.T
cells at varying time intervals after the third immunizing dose.
Delayed Hypersensitivity Test
The hind feet ofindividual mice were measured with a caliper before injection
ofsonicated E.A.T. cells into the soles and at varying intervals (6 hours, 24 hours,
48 hours) after injection. Sonicated cells were prepared by ultrasonic disintegra-
tion of washed E.A.T. cells (20 per cent suspension in saline). One foot was
injected with the sonicated cells (0.02 ml.) and the otherfoot withthe same volume
of saline as control. The mean increases in foot thickness at different intervals
after injection were calculated. Immunized and normal mice, each in groups of 8,
were compared for their response to sonicated cells.
Serological Determinations
The mice were bled at regular intervals from the tail vein and serum collected
and stored for serological determinations. Various tests were carried out in an
attempt to demonstrate circulating antibodies in the sera taken at different stages
of immunization. Normal mou. e serum and immune guinea-pig serum (from
animals injected with sonicated EA.T. cells in Freund's adjuvant) were used as
negative and positive controls.
(a) Double diffusion tests were performed using the micro-technique described
by Wadsworth (1957), with sonicated E.A.T. cell extracts and ascitic fluid as
antigen (both ofthese materials were used undiluted and diluted 1: 5 with saline).
(b) Phagocytosis of washed E.A.T. cells in the presence of immune sera by
guinea-pig peritoneal macrophages was tested by the method of Bennett (1965).
Macrophages were cultivated for 24 hours on glass coverslips in medium 199
containing guinea-pig serum. Mixtures of E.A.T. cells, guinea-pig serum, and
the serum to be tested were then added to the macrophage cultures and incubated
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for a further 11 hours. The coverslips were rinsed in saline, fixed in methanol-
acetic acid-water (90: 1: 9) and stained with buffered Giemsa. The stained
preparations were examined microscopically for ingestion of tumour cells by
macrophages.
(c) Agglutination tests were carried out with washed E.A.T. cells (3 per cent
suspension) and serial dilutions ofthe immune sera in Dulbecco phosphate buffer.
Coombs' test was also applied using E.A.T. cells pretreated with the immune
serum, with the further addition of goat anti-mouse y-globulin.
(d) Cytotoxic tests were performed with serial dilutions of the immune sera in
Dulbecco phosphate buffer in the presence of washed E.A.T. cells (3 per cent
suspension) and complement (1: 15 guinea-pig serum). Uptake of trypan blue
(0.01 per cent) was taken as the index of cytotoxic action and cell death.
Preparation ofVy and 72 globulins
Serum from immunized CBA mice (5 ml.) was treated with two volumes of
27 per cent (w/v) sodium sulphate and maintained at 370 C. overnight. The
precipitate was collected by centrifugation, dissolved in normal saline (2 ml.) and
dialysed against starting phosphate buffer (0.009 M K2HPO4, 0-001 M KH2PO4,
pH 7.9). This solution, containing mainly globulins, was applied to a DEAE-
cellulose (Whatman DE-1) column (2 x 40 cm.) previously equilibrated with the
same buffer. Chromatographic separation ofyV and 72 globulins was carried out
by stepwise elution using two phosphate buffers of different concentrations
(Reisfeld and Hyslop, 1966). Fahey, Wunderlich and Mishell (1964) have des-
cribed these two forms of 7S immunoglobulin in the mouse, and distinguished
them from two further immunoglobulins, namely YlA and iMl; the latter are
analogous to the YA andyM (IgA and IgM) of human serum.
72 globulin was eluted with the starting buffer and another eluant (0.282 M
K2HPO4, 0*018 M KH2PO4, pH 7.9) was then applied to elute y7 globulins. The
protein content in 3 ml. fractions of the eluate was estimated by measuring the
extinction at 280 m/t. Fractions comprising the first and second peaks were
concentrated separately by ultrafiltration, dialysed against Dulbecco phosphate
buffer, and stored at -20° C. until required.
Immunoelectrophoresis was performed by the method of Scheidegger (1955),
using Veronal buffer at pH 8*6 to characterize the differences in electrophoretic
mobility of the yV and 72 globulin fractions.
RESULTS
Resistance to challenge
The resistance of immunized mice to challenge with intraperitoneally injected
living E.A.T. cells at varying intervals after the third immunizing dose is sum-
marized in Table I.
It was found that a small proportion of the CBA mice immunized with iodo-
acetate-treated cells resisted challenge with 2-5 x 106 virulent cells administered
between 7and 17 daysafterthe course ofimmunization. However, all the immun-
ized white mice tested under identical conditions developed ascites tumours and
died within 15 days after the challenging dose of virulent cells. All the normal
mice injected with living E.A.T. cells developed ascites and died within 15 days
except one CBA in Batch I. It was later observed that in this animal small solid
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TABLE I.-Resistance ofImmunized Mice to Challenge with Living
E.A.T. Cells
Batch I: CBA Batch II: CBA Batch III:
Herston White
Days survivors at 22 days survivors at 30 days survivors at 15 days
after A =_ , A _A__
immunization immune normal immune normal immune normal
7 . . 2/14 0/14 . 0/14 0/14
10 3/5 1/5 . 3/13 0/13 . 0/13 0/13
14 . 0/5 0/5 . 2/13 0/13 . 0/13 0/13
17 . 1/5 0/5
tumours had developed subcutaneously. A difference in the rate of growth of
tumours between the immunized mice and normal mice after challenge was also
noted. A retardation of tumour growth was apparent in all the immunized CBA
mice but not in the Herston white strain.
Serological Determinations
Whole Sera.-Assay for circulating antibodies was carried out by the agar gel
double diffusion technique as well as by agglutination, phagocytic and cytotoxic
tests. No anti-tumour antibodies were detected in the immune whole sera by
any of these methods.
Antibody Fractions.-Agglutination, phagocytic and cytotoxic tests were
carried out on both the Y2 andyi globulin fractions separated by column chroma-
tography. No antibody activity was detected in the fractions by any of these
methods.
Delayed Hypersensitivity
Mice injected intraperitoneally with E.A.T. preparations according to various
schedules were tested for hypersensitivity to the tumour, and some of the results
are shown in Table II. A single injection of iodoacetate-treated cells was not
sufficient to induce hypersensitivity; however, two or more injections induced a
hypersensitivity which was evident at 24 and 48 hours (but not at 6 hours) after
the eliciting dose of sonicated cells, that is, a delayed-type hypersensitivity.
Most of the measurements were made with an interval of 7-11 days between the
last immunizing dose and the eliciting dose, but hypersensitivity was still found
in a group of mice tested 27 days after immunization. Although the recorded
differences in foot thickness for the hypersensitive mice were not very great, they
were observed regularly in many different experiments, and were statistically
highly significant (P < 0.001). The reactions of normal non-immunized mice
were not significant (P = 0.1-1.0).
There was no hypersensitivity to cell-free ascitic fluid or to iodoacetate-treated
E.A.T. cells, when these were used for the eliciting injections. Sonicated E.A.T.
cells were notefficientasimmunizing injections inthe induction ofhypersensitivity.
Both strains of mice responded equally well to the immunizing injections, as
shown by the development of delayed hypersensitivity.
There was no correlation between the degree ofreaction in the hypersensitivity
test and the ability of the mice to survive challenge; those mice which survived
were not necessarily those which had developed greatest hypersensitivity.
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6 . 0-04±0-046 . 0*4





24 . 0-17±0-026 . <0-001
24 . 0-12±0*045 .
24 . 0-05±0022 . 0-1




white . treated cells
Normal
white
48 . 0-02±0O020 . 0-5
3 8 24 . 009+0017 . <0-001
24 . 0-04±0O023 . 0-2
* Each injection consisted of 2 5 x 106f cells.
t Difference between increase in right foot thickness (injected with sonicated cells) and left foot
thickness (injected with saline).
t Significance of difference between antigen injected foot and saline injected foot.
DISCUSSION
Using techniques similar to those employed successfully by Apffel et al. (1966)
with A-jax mice, we have failed to induce effective immunity to E.A.T. in CBA and
Herston white mice. Immunization ofCBA mice with iodoacetate-treated tumour
cells led to slightly increased resistance to challenge with live tumour, as shown by
slower tumour growth and a higher proportion of survivors as compared with
control normal mice; however, the results were disappointing when compared with
those of the above investigators. We followed all details of the published pro-
cedure (Apffel et al., 1966), except for using different strains of mice and E.A.T. of
different recent history.
No evidence was found for the presence ofanti-tumour antibodies in the whole
serum, as might have been expected in the face ofthe poor response to challenge.
Nevertheless we fractionated pooled serum from immunized mice and separated
7S y, and 7S Y2 globulins, hoping to find antibody activity in the fractions. In
both mice and guinea-pigs, antibodies of these types have been separated and
found to have different serological properties (Bloch, 1965). The 7S Y2 antibodies
are of the cytolytic type, but their activity is reduced in the presence of 7S yT
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between antibodies ofthese types in certainsystems, and it wasthoughtthat such a
phenomenon might explain the apparent lack of resistance and absence of anti-
bodies in our mice. A balance between antitumour antibodies of)2 cytolytic type
and of yi anaphylactic type might be expected to result in lack of resistance to
tumour and serological inertness. There was, however, no detectable antibody
activity in either fraction. The inhibitor of oncolytic reactions, detected by
Hartveit (1964) in ascitic fluid of tumour-bearing mice, was presumably not the
cause of our negative results, since washed E.A.T. cells were used in all serological
tests.
The results ofiodoacetate treatment ofE.A.T. cells, as reported by Apffel et al.
(1966), could possibly have been due to activation or exposure of an antigen not
normally evident in the tumour. If this were a specific tumour antigen, it might
be expected to be immunogenic in all mouse strains. Ifthe antigen were a mouse
iso-antigen (such as a histocompatability antigen), it would be immunogenic only
in strains ofmice not naturally possessing it. The nature ofthe iso-antigens which
may be involved here is obscure, since the strain oforigin ofE.A.T. is not recorded.
As pointed out by others (Hauschka, 1952; Prehn and Main, 1957; Lindenmann,
1964), the difficulties in working with allogeneic transplantable tumours of
unknown origin are formidable. It should therefore be of great interest to
determine the effect of iodoacetate on the immunogenicity of chemically induced
tumours in the strain of origin. Experiments with methylcholanthrene-induced
ascites tumours in CBA mice are now being planned.
In spite ofthe apparent poor immune response ofCBA and Herston white mice
as judged by resistance to challenge and by circulating antibodies, injection of
iodoacetate-treated E.A.T. cells led to delayed-type hypersensitivity. By the
latter criterion, the mice hadresponded immunologically. In this sense, therefore,
we have confirmed the immunogenicity of iodoacetate-treated E.A.T. cells, but
we found no substantial tumour immunity to be associated with the hypersensi-
tivity. It is possible that a more impressive immunity would have been revealed
by challenge with smaller numbers ofE.A.T. cells.
The development of delayed-type hypersensitivity after immunization with
whole cells, as manifested by a local skin reaction to disrupted cells, is reminiscent
of the immune response to homografts (Brent, Brown and Medawar, 1958) and
raises the possibility that the antigens involved may be histocompatability
antigens. Irrespective of the tumour-specific or isoantigenic nature of the iodo-
acetate-treated E.A.T. cells, they are capable of stimulating an immune reaction.
In A-jax mice the reaction is apparently powerful enough to result in the rejection
of large doses of living tumour and thus in immunity to challenge; in the mice
used in this study (CBA and Herston white), only a moderate-but highly signifi-
cant-degree of hypersensitivity resulted, and immunity was minimal. The
Herston white strain was completely unprotected by the immunizing procedure,
although hypersensitivity was readily demonstrated.
It is concluded that the iodoacetate method described is not suitable in all
strains ofmice for immunization against challenge with E.A.T. Ifwe can assume
that the tumours used byApffel etal. (1966) and ourselves are antigenically similar,
then the different mouse strains have behaved differently towards immunization.
On the one hand, A-jax mice developed resistance to challenge (other immune
reactions were not reported); on the other hand, significant resistance to challenge
was not achieved in CBA or Herston white mice, although delayed-type hyper-
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sensitivity appeared. The existing data do not permit further speculation as to
the nature of the immune responses or of the antigens concerned.
SUMMARY
1. Mice of two different strains (CBA and Herston white) failed to develop
marked resistance to Ehrlich ascites tumour when immunized with iodoacetate-
treated tumour cells, a procedure reported by others to be effective in protecting
A-jax mice.
2. No circulating anti-tumour antibodies could be detected in the sera of the
immunized mice, by a variety oftechniques.
3. Delayed-type hypersensitivity to disrupted tumour cells was present in the
immunized mice to a highly significant degree; however, this was not correlated
with resistance to challenge with live tumour.
4. The possible reasons for the above observations are discussed.
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